# Harbour BioMed's Partner Spruce Biosciences Separates CRHX-101 Program into Adrenyx Biosciences, Advancing Development of Harbour BioMed-Originated Antibody through a Standalone Company

- Link: https://www.thailand-business-news.com/pr-news/harbour-biomeds-partner-spruce-biosciences-separates-crhx-101-program-into-adrenyx-biosciences-advancing-development-of-harbour-biomed-originated-antibody-through-a-standalone-company
- Published: 2026-11-18T07:02:00+07:00
- Author: PR Newswire

|   |

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 18, 2026 /PRNewswire/—
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company 
committed to the discovery and development of novel antibody therapeutics in immunology,
oncology and other areas, today announced that its partner Spruce Biosciences (Nasdaq:
SPRB) ("Spruce") has separated its CRHX-101 (formerly SPR-202 and HBM9013) program
into Adrenyx Biosciences ("Adrenyx").

Adrenyx is a newly established, wholly-owned subsidiary of Spruce focused on endocrinology.
This company is expected to be listed on Nasdaq in the first half of 2027. Upon 
completion of the planned pro rata distribution of Adrenyx common stock to Spruce
shareholders, Harbour BioMed expects to hold equity interests in both Spruce and
Adrenyx.

CRHX-101 is a monoclonal antibody designed to selectively neutralize corticotropin-
releasing hormone (CRH), an upstream driver of adrenal androgen excess in classic
congenital adrenal hyperplasia (CAH). By targeting CRH at the top of the hormonal
signaling cascade, CRHX-101 is being developed with the potential to achieve durable
upstream disease control and reduce patients’ reliance on chronic high-dose glucocorticoid
therapy, a longstanding challenge in CAH management. Adrenyx’s near-term priorities
include completion of IND-enabling nonclinical and chemistry, manufacturing and 
controls activities, the filing of an Investigational New Drug application for CRHX-
101 with the U.S. Food and Drug Administration (the "FDA"), and initiation of a 
clinical program thereafter.

To support the development of CRHX-101, Adrenyx has secured an initial US$5 million
under a secured convertible note purchase arrangement, with the potential to issue
up to US$10 million in aggregate principal amount. In addition, a private placement
of Adrenyx equity securities to institutional investors is expected to be completed
in connection with the planned distribution, with up to US$50 million funded by 
the convertible notes investor, inclusive of the notes funding.

Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed, commented: "We are
pleased to see the continued advancement of CRHX-101 through a dedicated corporate
structure. The establishment of Adrenyx reflects a focused approach to advancing
CRHX-101 and supporting its next stage of development. We look forward to the continued
progress of CRHX-101 in addressing the significant unmet medical needs of people
living with CAH."

CRHX-101 originated from HBM Alpha Therapeutics (HBMAT), an innovative biotechnology
company incubated by Harbour BioMed. In January 2025, HBMAT entered into a collaboration
and license agreement with Spruce, granting Spruce exclusive rights to develop and
commercialize this molecule outside Greater China (including mainland China, Hong
Kong, Macau and Taiwan). Under the agreement, HBMAT is eligible to receive up to
US$395 million, including upfront, development, regulatory and commercial milestone
payments, as well as tiered royalties on future net product sales. Additionally,
HBMAT was granted a warrant to receive minority interest in the partner. In January
2026, Harbour BioMed announced that its wholly-owned subsidiary had exercised the
warrants.

**About Harbour BioMed**

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to 
the discovery and development of novel antibody therapeutics in immunology, oncology
and other areas. The Company is building a robust portfolio and differentiated pipeline
through internal R&D capability, strategic global collaborations in co-discovery
and co-development, and selective acquisitions.

Our proprietary antibody technology platform, Harbour Mice^(®), generates fully 
human monoclonal antibodies in both the conventional two heavy and two light chain(
H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies,
the HCAb-based immune cell engagers (HBICE^(®)) bispecific antibody technology enables
tumor-killing effects that traditional combination therapies cannot achieve. The
HCAb-based Antibody Plus technology (HCAb PLUS™) provides comprehensive modality
solutions for the development of innovative multi-specific medicines in different
disease areas. Additionally, building upon the Harbour Mice^(®) platform, Harbour
BioMed launched its first fully human Generative AI HCAb Model powered by its Hu-
mAtrIx™ AI platform, accelerating the development of innovative therapies.

By integrating Harbour Mice^(®), HBICE^(®), HCAb PLUS™, a single B-cell cloning 
platform and AI technologies, Harbour BioMed has built a highly efficient and distinctive
antibody discovery engine for developing next-generation therapeutic antibodies.
For more information, please visit [www.harbourbiomed.com](http://www.harbourbiomed.com/).

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Harbour BioMed's Partner Spruce Biosciences Separates CRHX-101 Program into Adrenyx Biosciences, Advancing Development of Harbour BioMed-Originated Antibody through a Standalone Company ](https://en.prnasia.com/story/archive/5098036_CN98036_0?rand=184833)
